According to “Pfizer CEO says third Covid vaccine dose likely needed within 12 months” Pfizer (NYSE PFE) CEO Albert Bourla said people will “likely” need a booster dose of a Covid-19 vaccine within 12 months of getting fully vaccinated. His comments were made public Thursday but were taped April 1st, Bourla said it’s possible people will need to get vaccinated against the coronavirus annually.“A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed. And again, the variants will play a key role,” he told CNBC’s Bertha Coombs during an event with CVS Health.“It is extremely important to suppress the pool of people that can be susceptible to the virus,” Bourla said. The comment comes after Johnson & Johnson (NYSE:JNJ)CEO Alex Gorsky told CNBC in February that people may need to get vaccinated against Covid-19 annually, just like seasonal flu shots. Researchers still don’t know how long protection against the virus lasts once someone has been fully vaccinated. Pfizer said earlier this month that its Covid-19 vaccine was more than 91% effective at protecting against the coronavirus and more than 95% effective against severe disease up to six months after the second dose. Moderna’s (NASDAQ:MRNA) vaccine, which uses technology similar to Pfizer’s, was also shown to be highly effective at six months. Pfizer’s data was based on more than 12,000 vaccinated participants. However, researchers say more data is still needed to determine whether protection lasts after six months.
As big pharma races to save millions of lives there is a smaller less known “sleeping giant” in the CAR-T space developing advanced S-layer technology with limitless applications in the key development of an intranasal vaccine. S-Layer “surface layer” technology is used to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out. “We see our vaccine candidate as a complement to any injectable vaccines in clinical trials, because it could provide first-line immune protection at the virus’s entrance site”. Adding a coat of an S-layer onto solid surfaces can greatly improve the function of a therapeutic, vaccine, or device. The S-layer allows enhanced efficiency and interaction of targeted proteins and molecules for better function.
Avalon GloboCare is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation. Avalon also has research being done in MIT (Massachusetts Institute of Technology), the UNRLS (University of Natural Resources and life sciences in Australia), Weill Cornell Medicine in New York City and the Lu Daopei Medical Group in China, which has the country’s top ranked hematology and bone marrow transplant program
In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s President and CEO, David Jin, M.D., Ph.D., highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021. Dr. Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial (Avalon feature in Biopharma Dealmakers).
“We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” said Dr. Jin.
Avalon GloboCare, is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology who have a competitive advantage with their “S-Layer” technology in a vaccine market that is expected to grow to approximately 93.billion by 2026 according to Forbes business . This small cap biotechnology company is working towards the goal of changing the way we fight the devastating effects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant. With more upcoming catalysts in early 2021, it is safe to say that there is a large potential upside in AVCO’s stock is currently trading at its 52 week know at 1.00 in change , as the market is anticipating updates on their progress on multiple clinical trials, leaving the question most investors are asking themselves.” When will Avalon GloboCare (NASDAQ:AVCO) take off ?”
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.